Results 61 to 70 of about 70,715 (255)
Tofacitinib, a pan–Janus kinase inhibitor, and the Janus kinase 1–preferential inhibitors Upadacitinib and Filgotinib are approved for the treatment of ulcerative colitis, yet their molecular mechanisms of action remain incompletely understood.
Beibei Liu +32 more
doaj +1 more source
Identification of SH2-Bβ as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2 [PDF]
Janus kinases (JAKs) are cytoplasmic tyrosine kinases critical for signaling by growth hormone (GH) and many other ligands that bind to members of the cytokine receptor superfamily. SH2-Bβ was previously identified as a JAK2-interacting protein that is tyrosyl phosphorylated in response to GH and other cytokines that activate JAK2.
L, Rui, C, Carter-Su
openaire +2 more sources
SnRNA‐seq reveals cellular heterogeneity and proliferation mechanisms in limb venous malformations
To dissect the cellular heterogeneity and invasive mechanisms of limb venous malformations (VMs), this study first obtained tissue samples from four patients with VMs and four normal controls (NC). Single‐nucleus suspension was prepared, followed by transcriptome library construction and sequencing. After pretreatment, quality control, standardization,
Junjie Lin +13 more
wiley +1 more source
Native postbiotics and paraprobiotics derived from Lactobacillus and Bifidobacterium strains were administered to dextran sulfate sodium–treated C57BL/6 mice to evaluate their impact on kidney inflammation via the gut–kidney axis. Histological analysis and quantitative polymerase chain reaction of autophagy‐related genes (atg5, atg7, atg12, atg13 ...
Fatemeh Haririzadeh Jouriani +6 more
wiley +1 more source
CAQ Corner: Basic concepts of transplant immunology
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib
Ruxolitinib is a targeted agent that inhibits Janus 2 Kinase and is approved for use in Polycythemia Vera and Primary Myelofibrosis. Its mechanism of action involves inhibition of cellular proliferation via the Janus kinase/signal transducer and ...
Ramy M. Hanna +3 more
doaj +1 more source
Phenylhydrazine (PHZ) induces hemolytic anemia characterized by increased erythrocyte destruction and ineffective erythropoiesis, leading to hepcidin suppression through disruption of the BMP/SMAD signaling pathway. Reduced hepcidin levels enhance intestinal iron absorption and hepatic iron accumulation, leading to hepatic iron overload.
Mohammad Indra Pratama +5 more
wiley +1 more source
Background Non‐melanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with Janus kinase inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Method This study used data from the British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR‐RA) linked
Zixing Tian +8 more
wiley +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
TYK2 in Immune Responses and Treatment of Psoriasis
Lin Shang,* Jiali Cao,* Siqi Zhao, Jingya Zhang, Yanling He Department of Dermatology, Capital Medical University Affiliated Beijing Chaoyang Hospital, Beijing, People’s Republic of China*These authors contributed equally to this ...
Shang L, Cao J, Zhao S, Zhang J, He Y
doaj

